Abstract
Methamphetamine (METH) has been shown to induce neurotoxicity. In a previous human study using quantitative Western blotting and radioligand binding assay, dopaminergic terminal marker deficits were induced in chronic METH users. In this study, we examined the suitability of the immunohistochemical detection of tyrosine hydroxylase (TH), dopamine transporter (DAT), and vesicular monoamine transporter-2 (VMAT2) levels, and caspase-3 activation in the striatum to diagnose METH abuse. Decreases in TH immunoreactivity in the nucleus accumbens and DAT in the nucleus accumbens and putamen were induced in METH users, whereas a significant difference of VMAT2 was not evident between METH and control groups. However, in the nucleus accumbens of two METH users, levels of VMAT2, a stable marker of striatal dopaminergic terminal integrity, were reduced remarkably. These findings might indicate that dopaminergic terminal degeneration is induced in the striatum of some METH abusers. On the other hand, we observed little caspase-3 activation, indicative of apoptosis, in the striatal neurons of chronic METH users. Overall, the findings of dopaminergic terminal markers were similar to those in the previous human study. Therefore, it is suggested that immunohistochemical techniques could be used to examine dopaminergic terminal marker levels and could also give useful information on chronic and/or lethal METH use in cases of METH-related death, where METH intoxication may not be toxicologically demonstrated.
Similar content being viewed by others
References
Anderson AJ, Su JH, Cotman CW (1996) DNA damage and apoptosis in Alzheimer’s disease: colocalization with c-Jun immunoreactivity, relationship to brain area and effect of postmortem delay. J Neurosci 16:1710–1719
Cadet JL, Brannock C (1998) Free radicals and the pathology of brain dopamine systems. Neurochem Int 32:117–131
Cadet JL, Jayanthi S, Deng X (2003) Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17:1775–1788
Cappon GD, Pu C, Vorhees CV (2000) Time-course of methamphetamine-induced neurotoxicity in rat caudate–putamen after single dose treatment. Brain Res 863:106–111
Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, Mufson EJ, Mash DC, Levey AI (1999) Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409:38–56
Deng X, Wang Y, Chou J, Cadet JL (2001) Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method. Brain Res Mol Brain Res 93:64–69
De Vito MJ, Wagner GC (1989) Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 28:1145–1150
Dreßler J, Hanisch U, Busuttil A (2005) Comments on Hausmann et al.: neuronal apoptosis following human brain injury. Int J Legal Med 119:177–178
Frey K, Kilbourn M, Robinson T (1997) Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 334:273–279
Gown AM, Willingham MC (2002) Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 50:449–454
Guilarte TR, Nihei MK, McGlothan JL, Howard AS (2003) Methamphetamine-induced deficits of monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 122:499–513
Harvey DC, Lacan G, Tanious SP, Melega WP (2000) Recovery from methamphetamine-induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 871:259–270
Hausmann R, Kaiser A, Lang C, Bohnert M, Betz P (1999) Quantitative immunohistochemical study on the time-dependent course of acute inflammatory cellular response to human brain injury. Int J Legal Med 112:227–232
Hausmann R, Biermann T, Wiest I, Tübel J, Betz P (2004) Neuronal apoptosis following brain injury. Int J Legal Med 118:32–36
Hausmann R, Vogel C, Seidl S, Betz P (2006) Value of morphological parameters for grading of brain swelling. Int J Legal Med (in press). DOI 10.1007/s00414-005-0021-6
Hogan KA, Staal RGW, Sonsalla PK (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicular preparations. J Neurochem 74:2217–2220
Jayanthi S, Deng X, Noailles P-AH, Ladenheim B, Cadet JL (2004) Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondrial-dependent death cascades. FASEB J 18:238–251
Johnson-Davis KL, Fleckenstein AE, Wilkins DG (2003) The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur J Pharmacol 482:151–154
Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 15:8951–8960
Matsuzaki H, Namikawa K, Kiyama H, Mori N, Sato K (2004) Brain-derived neurotrophic factor rescues neuronal death induced by methamphetamine. Biol Psychiatry 55:52–60
Meredith GE, Callen S, Scheuer DA (2002) Brain-derived neurotrophic factor expression in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 949:218–227
Mirecki A, Fitzmaurice P, Ang L, Kalasinski KS, Peretti FJ, Aiken SS, Wickham DJ, Sherwin A, Nobrega JN, Forman HJ, Kish SJ (2004) Brain antioxidant systems in human methamphetamine users. J Neurochem 89:1396–1408
O’Callaghan JP, Miller B (1994) Neurotoxicity profiles of substituted amphetamine in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741–751
Segal DS, Kuczenski R, O’Neil ML, Melega WP, Cho AK (2003) Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28:1730–1740
Vander Borght TM, Kilbourn MR, Desmond T, Kuhl D, Frey K (1995) The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294:577–583
Williams SM, Bryan-Lluka LJ, Pow DV (2005) Quantitative analysis of immunolabeling for serotonin and for glutamate transporter after administration of imipramine and citalopram. Brain Res 1042:224–232
Wilson JM, Kalasinski KS, Levey AI, Bergeron C, Reiber G, Anthony RT, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699–703
Acknowledgement
This work was supported by grants-in-aid for General Scientific Research (17590579) from the Ministry of Education, Science, Sports and Culture of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kitamura, O., Tokunaga, I., Gotohda, T. et al. Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int J Legal Med 121, 163–168 (2007). https://doi.org/10.1007/s00414-006-0087-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00414-006-0087-9